Targeting P2Y12 limits TH17 accumulation in the CNS and reduces EAE progression

Niklas Huntemann, Lara-Maria Preuth, Thorsten F. Krug, Anna Vogelsang, Linda Groeneweg, Paul Disse, Rajeevan Narayanan Therpurakal, Alexander Zarbock, Bernhard Nieswandt, Kerstin Göbel, Harald F. Langer, Tobias Ruck, Antje Schmidt-Pogoda, Amin Polzin, Susann Eichler, Sven G. Meuth

Open source

DOI: 10.3389/fimmu.2026.1946414
Published: 2026-10-21
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1946414,
  title = {Targeting P2Y12 limits TH17 accumulation in the CNS and reduces EAE progression},
  author = {Niklas Huntemann and Lara-Maria Preuth and Thorsten F. Krug and Anna Vogelsang and Linda Groeneweg and Paul Disse and Rajeevan Narayanan Therpurakal and Alexander Zarbock and Bernhard Nieswandt and Kerstin Göbel and Harald F. Langer and Tobias Ruck and Antje Schmidt-Pogoda and Amin Polzin and Susann Eichler and Sven G. Meuth},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1946414},
  url = {https://doi.org/10.3389/fimmu.2026.1946414}
}

RIS

TY  - JOUR
TI  - Targeting P2Y12 limits TH17 accumulation in the CNS and reduces EAE progression
AU  - Niklas Huntemann
AU  - Lara-Maria Preuth
AU  - Thorsten F. Krug
AU  - Anna Vogelsang
AU  - Linda Groeneweg
AU  - Paul Disse
AU  - Rajeevan Narayanan Therpurakal
AU  - Alexander Zarbock
AU  - Bernhard Nieswandt
AU  - Kerstin Göbel
AU  - Harald F. Langer
AU  - Tobias Ruck
AU  - Antje Schmidt-Pogoda
AU  - Amin Polzin
AU  - Susann Eichler
AU  - Sven G. Meuth
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1946414
UR  - https://doi.org/10.3389/fimmu.2026.1946414
ER  -

APA

Huntemann, N., Preuth, L., Krug, T. F., Vogelsang, A., Groeneweg, L., Disse, P., Therpurakal, R. N., Zarbock, A., Nieswandt, B., Göbel, K., Langer, H. F., Ruck, T., Schmidt-Pogoda, A., Polzin, A., Eichler, S., & Meuth, S. G. (2026). Targeting P2Y12 limits TH17 accumulation in the CNS and reduces EAE progression. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1946414

Source records

crossref · retrieved 2026-11-10T12:32:53.992Z